Log in

NASDAQ:ARDSAridis Pharmaceuticals Earnings Date, Estimates & History

$8.40
+0.67 (+8.67 %)
(As of 05/25/2020 04:00 PM ET)
Add
Compare
Today's Range
$7.63
Now: $8.40
$8.50
50-Day Range
$5.29
MA: $6.97
$8.97
52-Week Range
$3.80
Now: $8.40
$12.40
Volume1,612 shs
Average Volume9,045 shs
Market Capitalization$74.93 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.01

Earnings

Aridis Pharmaceuticals (NASDAQ:ARDS) Earnings Information

Aridis Pharmaceuticals last released its quarterly earnings results on May 12th, 2020. The reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $0.06. Aridis Pharmaceuticals has generated ($3.51) earnings per share over the last year. Aridis Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 10th, 2020 based off prior year's report dates.

Aridis Pharmaceuticals Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Aridis Pharmaceuticals (NASDAQ:ARDS) Earnings Estimates

Current Year EPS Consensus Estimate: $-3.02 EPS
Next Year EPS Consensus Estimate: $-2.53 EPS

Aridis Pharmaceuticals (NASDAQ ARDS) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSGAAP EPSRevenue EstimateActual RevenueConference CallDetails
8/10/2020
(Estimated)
       
5/12/2020Q1 2020($0.67)($0.73)($0.73)$0.75 millionN/A
4/8/2020Q4($0.8080)($0.63)($0.63)N/A
11/13/2019Q3($0.33)($0.87)($0.87)$1.50 millionN/A
8/12/2019Q2 2019($0.84)($1.03)($1.03)N/A
5/14/2019Q1($0.8670)($0.99)($0.99)$1.02 millionN/A
3/28/2019Q4($1.5530)($0.67)($0.67)$0.30 million$1.39 millionN/A
11/13/2018Q3 2018($1.05)($1.97)($1.27)$0.33 million$1.02 millionN/A
(Earnings results data provided by Zacks Investment Research)
This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.